OPC-34712 + ADT

DRUG2 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

DepressionDepressive DisorderDepressive Disorder, MajorMental DisordersMood Disorders

Phase 3

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)

CompletedNCT01360632

Otsuka Pharmaceutical Development & Commercialization, Inc.Depression, Depressive Disorder, Depressive Disorder, Major +2

Start: 2011-06-30End: 2013-09-30Updated: 2016-01-01

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)

CompletedNCT01360645

Otsuka Pharmaceutical Development & Commercialization, Inc.Depression, Depressive Disorder, Depressive Disorder, Major +2

Start: 2011-07-31End: 2013-06-30Updated: 2015-11-26

Related Papers

Adjunctive brexpiprazole in patients with major depressive disorder who show minimal or partial response to antidepressant treatment: post hoc analysis of randomized controlled trials.

2025-10-01

Effects of adjunctive brexpiprazole in patients with major depressive disorder and sleep disturbance: a post hoc analysis of three randomized trials

Frontiers in Psychiatry2025-08-072 citations

Adjunctive Brexpiprazole in Patients With Unresolved Symptoms of Depression on Antidepressant Treatment Who are Early in the Disease Course: <i>Post Hoc</i> Analysis of Randomized Controlled Trials

The International Journal of Neuropsychopharmacology2025-07-03

A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder

CNS Drugs2024-10-182 citations

Effects of Adjunctive Brexpiprazole on Individual Depressive Symptoms and Functioning in Patients With Major Depressive Disorder and Anxious Distress

Journal of Clinical Psychopharmacology2024-02-294 citations

Changes in Metabolic Parameters and Body Weight in Patients With Prediabetes Treated With Adjunctive Brexpiprazole for Major Depressive Disorder

The Journal of Clinical Psychiatry2023-08-244 citations

Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole

The Journal of Clinical Psychiatry2019-10-0112 citations

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

Journal of Clinical Psychopharmacology2019-04-0224 citations

Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale.

2019-03-0116 citations

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies.

2018-12-2019 citations

123 Adjunctive Brexpiprazole in Patients With MDD and Symptoms of Anxiety: Results From Post-Hoc Analyses of Three Placebo-Controlled Studies

CNS Spectrums2018-02-01

Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials.

2016-05-1225 citations

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder

The Journal of Clinical Psychiatry2015-08-03171 citations

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants

The Journal of Clinical Psychiatry2015-08-03160 citations